Soc. Generale Knock-Out GNMSF/ DE000CL7HDD0 /
5/30/2024 8:21:31 AM | Chg.-0.11 | Bid8:25:07 AM | Ask8:25:07 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
5.32EUR | -2.03% | 5.32 Bid Size: 600 |
5.62 Ask Size: 600 |
Genmab A/S | 1,533.2516 - | 12/31/2078 | Call |
GlobeNewswire
4/30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
4/3
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
10/17/2023
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
9/25/2023
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
9/4/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
10/19/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
9/20/2021
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
7/21/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021